IFF Announces Board of Directors Changes
IFF (NYSE: IFF) today unveiled the next phase in the evolution of its Board of Directors, aimed at bolstering the company's long-term strategic vision and driving profitable market share growth.
New Board Chair: Kevin O’Byrne—an experienced IFF board member and chair of Centrica plc—will become Board Chair at the 2025 Annual Shareholder Meeting. O’Byrne will succeed Roger W. Ferguson, Jr. who has served as Chair since 2022. Ferguson notified IFF of his intent to not stand for reelection at the 2025 Annual Shareholder Meeting after 14 years of distinguished service.
Board Appointments: Cynthia Jamison, Dr. Mehmood Khan and Vincent Intrieri will join the Board of Directors effective Jan. 1, 2025. Intrieri’s appointment is at the request of Icahn Capital LP pursuant to the Cooperation agreement. He replaces Gary Hu, who will step down from the IFF Board on Dec. 31, 2024.
Board Retirements: Christina Gold and John Davidson have announced their plans to not stand for reelection at the 2025 Annual Shareholder Meeting. When these departures are in effect, IFF will have ten board members.
“It has been an incredible honor and privilege to serve on the IFF Board,” said Ferguson. “IFF has the right leaders in place, a dynamic team fueled by science and creativity, plus a world-class portfolio backed by a cutting-edge R&D pipeline. The Company is very well placed to meet the needs of its customers, powering everyday products for tomorrow’s consumers. I am very proud of the strong progress in the last twelve months and excited to see IFF build on this momentum in the coming years. I want to thank Erik and the entire team at IFF for their commitment and support.”
“We are grateful for Roger, Christina, John and Gary's invaluable contributions to strengthening IFF,” said Erik Fyrwald, IFF CEO and director. “As we author our next chapter, I look forward to working with Kevin in his new role. I am delighted to welcome Cindie, Mehmood and Vince to the board. Their expertise, experience and insights will support us in unlocking our full potential to serve our customers, deliver innovative, sustainable solutions, and profitably grow IFF.”
About Cynthia Jamison
Cynthia “Cindie” Jamison is a seasoned executive with more than two decades of corporate boardroom and financial leadership experience. She currently chairs the boards of Darden Restaurants and Big Lots, and previously chaired Tractor Supply Co.
Before focusing on board service, Jamison was the CFO of AquaSpy, Inc. and held CFO roles at various companies during periods of growth or turnaround. From 1999-2009, she was a managing partner at Tatum LLP, leading the CFO Services practice and overseeing more than 400 CFOs nationally. She also served as CFO or COO for several companies, including eMac, Inc., Cosi, Inc., SurePayroll and Illinois Superconductor.
Her earlier career includes roles at Chart House Enterprises, Allied Domecq Retailing USA, Kraft General Foods and Arthur Andersen LLP.
Jamison is recognized as an expert in financial and economic issues, frequently speaking on topics related to CFOs and board governance. She has been quoted in Forbes, The Wall Street Journal, Newsweek and The Economist. She is an NACD Board Leadership Fellow named among the NACD D100.
About Mehmood Khan
Dr. Mehmood Khan is the CEO of Hevolution Foundation, a first-of-its-kind global non-profit organization with a mission to extend healthy lifespan for people everywhere. Hevolution provides grants and early-stage company investments to incentivize independent research and entrepreneurship in the emerging field of healthspan science. The organization aims to increase the number of safe and effective treatments entering the market, compress the timeline of drug development using the latest tools and technologies, and increase accessibility to therapeutics. Hevolution has committed more than $400 million in grants, partnerships and early-stage biotech investments in just over two years, making it the world’s largest philanthropic healthspan science funder.
Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority and the Saudi National Biotechnology Strategy Steering Committee.
He previously served as a Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology, and as the Executive Chair of Life Biosciences after serving as the CEO from 2019-2024. Life Biosciences is based in Boston and leverages a platform approach to develop therapeutics that can reverse and prevent multiple age-related conditions.
Prior to this role, Dr. Khan served as PepsiCo’s Vice Chairman and Chief Scientific Officer of Global Research and Development. With net revenues of more than $64 billion in 2018, Dr. Khan oversaw the PepsiCo global Performance with Purpose sustainability initiatives, inspired by the fundamental belief that business success is inextricably linked to the sustainability of the world we share. He led PepsiCo’s research and development efforts, creating breakthrough innovations in food, beverages and nutrition—as well as delivery, packaging and production technology—to capture competitive advantage and drive PepsiCo’s businesses forward.
Prior to joining PepsiCo, Dr. Khan was President of Takeda Global Research & Development Center, overseeing Takeda Pharmaceuticals Company’s worldwide R&D efforts. He was also a faculty member at the Mayo Clinic and Mayo Medical School in Rochester, Minn., serving as Director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition for the Hennepin County Medical Center in Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology and an Elected Fellow in the Department of Pharmacology at University of Oxford.
About Vincent Intrieri
Vince Intrieri is the founder and CEO of VDA Capital Management LLC, a private investment fund established in 2017. Intrieri previously worked for Carl Icahn-related entities in various investment roles from 1998 to 2016, including serving as senior managing director of Icahn Capital LP from 2008 to 2016.
Intrieri is currently a Director of Transocean Ltd, Hertz Global Holdings and Chairman of the Board of Sandridge Energy Inc. His past directorships include Navistar International Corp., Energen Corp., Conduent Inc., Chesapeake Energy Corp., CVR Refining GP LLC, Ferrous Resources Ltd., Forest Laboratories Inc., CVR Energy Inc., Federal-Mogul Holdings Corp., Icahn Enterprises LP, Dynegy Inc., PSC Metals, Motorola Solutions Inc., XO Holdings, National Energy Group, American Railcar Industries, WestPoint Home LLC and Viskase Companies Inc.
Intrieri graduated with distinction from Pennsylvania State University with a B.S. in accounting in 1984 and was a certified public accountant.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219567125/en/
Contacts
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom